{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T23:01:22Z","timestamp":1754262082649,"version":"3.40.3"},"publisher-location":"Cham","reference-count":9,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783031044014"},{"type":"electronic","value":"9783031044021"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-031-04402-1_12","type":"book-chapter","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T10:08:30Z","timestamp":1669802910000},"page":"161-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating Novel Genetic Markers for Fluoroquinolone Associated Disorders"],"prefix":"10.1007","author":[{"given":"Andrew","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"12_CR1","unstructured":"FDA Briefing Document - Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (2015). The benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of Acute Bacterial Sinusitis (ABS), Acute Bacterial Exacerbation of Chronic Bronchitis in Patients Who Have Chronic Obstructive Pulmonary Disease (ABECB-COPD), and uncomplicated urinary tract infections (uUTI). https:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/anti-infectivedrugsadvisorycommittee\/ucm467383.pdf. Accessed 51 May \/2021"},{"key":"12_CR2","unstructured":"Bennett A, Qureshi ZP, Bennett CL (2017) A novel genetic marker has been identified in patients with FQ-associated neuropsychatric toxicity. Conference proceedings for the Association of veterans administration hematologist and oncologist. (abstract 55). https:\/\/www.mdedge.com\/fedprac\/avaho\/article\/146822\/novel-genetic-marker-has-been-identified-patients-fluoroquinolone. Accessed 1 May 2021"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/d41586-018-03267-5","volume":"555","author":"J Marchant","year":"2018","unstructured":"Marchant J (2018) When antibiotics turn toxic. Nature 555:431\u2013433","journal-title":"Nature"},{"key":"12_CR4","unstructured":"Woodcock J (2015) FDA. Denial response from FDA to the Southern Network on Adverse Reactions (SONAR) regarding levaquin and mitochrondrial toxicity. https:\/\/www.regulations.gov\/document?D=FDA-2014-P-1505-0005. Accessed 1 May 2021"},{"key":"12_CR5","unstructured":"Woodcock J (2018) FDA. Partial approval and partial denial response from FDA to the Southern Network on Adverse Reactions (SONAR) regarding levaquin. https:\/\/www.regulations.gov\/document?D=FDA-2014-P-1611-0005. Accessed 1 May 2021"},{"key":"12_CR6","doi-asserted-by":"publisher","unstructured":"Kaur K, Fayad R, Saxena A, Frizzell N, Chanda A, Das S, The Southern Network on Adverse Reactions (SONAR) project (2016) Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network.\u00a0J Commun Support Oncol\u00a014(2):54\u201365. https:\/\/doi.org\/10.12788\/jcso.0167","DOI":"10.12788\/jcso.0167"},{"key":"12_CR7","doi-asserted-by":"publisher","unstructured":"Werck-Reichhart D, Feyereisen R (2021) Cytochromes P450: a success story.\u00a0Genome Biol 2000. https:\/\/genomebiology.biomedcentral.com\/articles, https:\/\/doi.org\/10.1186\/gb-2000-1-6-reviews3003. Accessed 1 May 2021","DOI":"10.1186\/gb-2000-1-6-reviews3003."},{"key":"12_CR8","doi-asserted-by":"crossref","unstructured":"Lu K, Mahbub, Ridwan, Fox, James G (2018) Xenobiotics: interaction with the intestinal microflora. ILAR J\u00a056:218\u2013227","DOI":"10.1093\/ilar\/ilv018"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00008571-199706000-00004","volume":"7","author":"D Marez","year":"1997","unstructured":"Marez D, Legrand M, Sabbagh N et al (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193\u2013202","journal-title":"Pharmacogenetics"}],"container-title":["Cancer Treatment and Research","Cancer Drug Safety and Public Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-04402-1_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T10:09:38Z","timestamp":1669802978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-04402-1_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031044014","9783031044021"],"references-count":9,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-04402-1_12","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"type":"print","value":"0927-3042"},{"type":"electronic","value":"2509-8497"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"1 December 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}